NR1H4 and steatosis: Beyond beneficial effects on certain lipogenic enzymes, treatment with the FXR activator (FXRa) also induced a marked steatosis reduction with a similar extent in both genetic and FFA models (roughly 50%) (Fig. 3c,d).